Vir Biotechnology, Inc. Common Stock (VIR) is a publicly traded Healthcare sector company. As of May 21, 2026, VIR trades at $8.92 with a market cap of $1.48B and a P/E ratio of -2.83. VIR moved +4.10% today. Year to date, VIR is +53.37%; over the trailing twelve months it is +87.74%. Its 52-week range spans $4.16 to $14.45. Analyst consensus is strong buy with an average price target of $20.63. Rallies surfaces VIR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vir Biotechnology’s VIR-5500 Delivers 82% PSA50, 53% PSA90 and Secures Astellas Collaboration: Vir Biotechnology’s Phase 1 trial of VIR-5500 in metastatic prostate cancer showed dose-dependent anti-tumor activity, with 82% PSA50 declines, 53% PSA90 declines and objective responses in 45% of RECIST-evaluable patients at higher dose cohorts. It signed a collaboration with Astellas and plans a registrational trial in 2027.
| Metric | Value |
|---|---|
| Price | $8.92 |
| Market Cap | $1.48B |
| P/E Ratio | -2.83 |
| EPS | $-3.12 |
| Dividend Yield | 0.03% |
| 52-Week High | $14.45 |
| 52-Week Low | $4.16 |
| Volume | 34 |
| Avg Volume | 0 |
| Revenue (TTM) | $65.50M |
| Net Income | $-442.72M |
| Gross Margin | 0.00% |
9 analysts cover VIR: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.63.